Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTRU200 in Relapsed/Refractory AML, HR-MDS, DLBCL Post-CART Failure and Advanced Solid Tumors
NCT07749976Phase 2Not yet recruiting
- Sponsor
- VITRUVIAE
- Start
- Jan 2027
- Primary completion
- Jan 2028
01
Overview
A Phase 2 trial of VTRU200 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma (DLBCL), solid tumor, sponsored by VITRUVIAE. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
VTRU200
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)diffuse large B-cell lymphoma (DLBCL)solid tumor
Beyond the preview
Go deeper on NCT07749976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749976.